Primary aldosteronism management depends on a multitude of factors, and surgical adrenalectomy is generally recommended in ...

Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease ...

Formal written minutes from the U.S. FDA confirms no major concerns identified for the planned Phase 3 PANDA study of ...

AstraZeneca notes baxdrostat shows reduction in systolic blood pressure in phase III of uncontrolled or resistant hypertension: Our Bureau, Bengaluru Monday, January 5, 2026, 18:0 ...

Mineralys (MLYS) is transitioning to a pre-commercial stage, supported by robust Phase 3 data and a strengthened cash position of $593.6 million.

Formal written minutes from the U.S. FDA confirms no major concerns identified for the planned Phase 3 PANDA study of [68Ga]Ga-PentixaFor in treatment-resistant hypertension and Primary AldosteronismT ...

Jiangsu Deyuan Pharmaceutical Co. Ltd. has described cytochrome P450 11B2, mitochondrial (CYP11B2; aldosterone synthase; ALDOS) inhibitors reported to be useful for the treatment of hypertension.

The year saw the emergence of a new version of an old drug that proved beneficial in patients who have heart failure with ...

The trial was aimed at evaluating the efficacy, safety, and pharmacokinetics of Atumelnant when administered for 12 weeks in ...

CSPC Pharmaceutical Group Ltd. has obtained approval from the National Medical Products Administration (NMPA) in China to conduct clinical trials of SYH-2072 (tablets), a highly selective and potent ...